Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Kyowa Kirin Co., Ltd.
Takeda
University of North Carolina, Chapel Hill
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH